Retina Global is governed by the Board of Directors.
The current board members are:
- Mike T Trese, MD, USA
- Julia A Haller, MD, USA
- Suber S Huang, MD MBA, USA
- David E I Pyott, CBE, USA
- Francesco Bandello, MD, Italy
- Alan C Bird, MD, UK
- Jose-Alain Sahel, MD, France
- Susan Orr, OD, USA
- Adrienne L Graves, PhD, USA
- Ram Palanki, PharmD, USA
- Pravin Dugel, MD, USA
- Tien Yin Wong, MD PhD, Singapore
- Rajat N Agrawal, MD MS, CEO, USA
Dr. Trese received his undergraduate degree from the University of Michigan, his O.D. from Pennsylvania College of Optometry, and earned his M.D. degree from Georgetown University, School of Medicine. Dr. Trese served as Director of Vitreoretinal Surgery at the University of Kansas prior to joining Associated Retinal Consultants in 1982. He currently is Clinical Professor of Biomedical Sciences at The Eye Research Institute of Oakland University, Clinical Associate Professor at Wayne State University School of Medicine, and Chief of Pediatric and Adult Vitreoretinal Surgery at William Beaumont Hospital.
Dr. Trese is an internationally recognized expert in retinopathy of prematurity and pediatric retinal disease. His current basic science and clinical research interests encompass both pediatric and adult retinal disorders, including participation in National Institute of Health and National Eye Institute sponsored trials. He has spoken all around the world, delivered several named lectureships, and has authored numerous publications and textbook chapters.
Dr Trese is currently the Chairman of the Board of Directors.
Dr. Julia A. Haller is Ophthalmologist-in-Chief of the Wills Eye Institute, and Professor and Chair of the Department of Ophthalmology at Thomas Jefferson University. She was educated at the Bryn Mawr School in Baltimore, Princeton University, and Harvard Medical School. She interned in the Halsted surgery program at Johns Hopkins Hospital and spent a year with Dr. Frederick A. Jakobiec as a fellow in ocular pathology at Manhattan Eye, Ear and Throat Hospital and Cornell Medical Center. After a residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins Hospital, and a retina fellowship there with Ronald G. Michels, MD, she became Wilmer’s first female chief resident in 1986. She joined the faculty as assistant professor at Johns Hopkins in 1987, became the inaugural Katharine Graham Professor of Ophthalmology in 2002, and was installed as the inaugural Robert Bond Welch, MD professor of ophthalmology in 2006. At Wilmer, she directed the retina fellowship program. She assumed leadership of the Wills Eye Institute in November, 2007.
Dr. Haller has published over 250 papers in peer-reviewed literature as well as 20 book chapters. She is past president of the American Society of Retina Specialists and serves on the editorial boards of RETINA, Retinal Physician, Ocular Surgery News, Ophthalmology Times, and Evidence-Based Ophthalmology.
Dr Haller is currently the Secretary of the Board of Directors.
Dr. Huang is President of the American Society of Retina Specialists and has served on the Steering Committee for the National Eye Health Education Program, an advisory board to the National Eye Institute/National Institutes of Health, since 2003. He is also Vice-chair and Philip F. and Elizabeth G. Searle Professor of the Department of Ophthalmology and Visual Sciences at the Case Western Reserve University, and Director, Center for Retina and Macular Disease and the Retinal Diseases Image Analysis Reading Center at University Hospitals Case Medical Center. He is certified by the American Board of Ophthalmology, and serves on the Board of Directors for the Northeast Ohio Juvenile Diabetes Research Foundation and the University School. He is also Chair, Diabetic Eye Disease program at NEHEP/NEI/NIH, and Chair, Research, Regulatory, and Federal Affairs committee for the American Academy of Ophthalmology.
Dr. Huang received his undergraduate degree from the Johns Hopkins University, his medical degree in 1990 from the Albert Einstein College of Medicine, and his MBA in 2004 from the Weatherhead School of Management, Case Western Reserve University. He completed his ophthalmology residency training at the Wilmer Ophthalmological Institute at Johns Hopkins University and a fellowship in vitreoretinal diseases and surgery from the Bascom Palmer Eye Institute at the University of Miami.
Dr Huang is currently the Treasurer of the Board of Directors.
Mr David Pyott, CBE, is the former Chairman of the Board and Chief Executive Officer of Allergan. During his 17 year tenure, the company went from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014. Mr. Pyott has been recognized by prominent and well-respected business organizations many times, such as the Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4) and as the “#1 CEO in Specialty Pharmaceuticals” by Institutional Investor magazine in 2007, as well as the “Best CEO Healthcare – Pharmaceuticals” in 2013.
In 2006, Mr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgement of his contribution to British business excellence and management skills in the United States. In 2010, he received an honorary degree, the UCI Medal, and the Moacyr Gold Medal for services to Brazilian ophthalmology.
Before joining Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG, working over 17 years in several positions in strategic planning, marketing and general management in Switzerland, Austria, Spain, Malaysia and the United States.
Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.
Mr. Pyott is also the Lead Director and a member of the Board of Directors of Avery Dennison Corporation and a member of the Supervisory Board of Royal Philips in the Netherlands. He is Vice Chairman of the Board of Trustees of Chapman University, a member of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation and is on the Advisory Board of the Foundation of the American Academy of Ophthalmology. He formerly served on the Board, on the Executive Committee and as Board Secretary of the Biotechnology Industry Organization as well as a member of the Board of Edwards Lifesciences Corporation.
Francesco Bandello is Full Professor and Chairman at the Department of Ophthalmology at University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy. He is Academic Dean of “Corso di Laurea Specialistica/Magistrale in Medicina e Chirurgia” at the same University. He is also the President of EURETINA, President of Academia Ophthalmologica Europea and Vice-President of EuroLam.
Prof. Bandello is Co-Editor of the European Journal of Ophthalmology and former board member of the Club Jules Gonin and Macula Society. He is member of Executive Board of ESASO Foundation (European School for Advanced Studies in Ophthalmology), member of the Academia Ophthalmologica Internationalis and the Accademia Nazionale di Medicina. Prof. Bandello is co-author of 9 books and he serves as a peer reviewer for grant applications for the NEI. He has authored or co-authored 282 articles and he served as trained Principal Investigator in several clinical trials performed following ICH/GCP and mainly concerning retinal diseases.
Prof Bird retired from full time clinical practice in 2005, to focus on research and teaching. A well-known retinal expert around the world, Prof Bird started his career at the Institute of Ophthalmology as a Lecturer in 1969, after residency training in Ophthalmology at the Moorfields Eye Hospital, Senior Registrar at The London Hospital and The Hospital for Nervous Diseases, Queen Square, followed by a Fellowship in neuro-ophthalmology at Bascom Palmer Eye Institute with Dr. Lawton Smith and a brief period with Dr Hoyt in San Francisco. Subsequently, Prof Bird was appointed as Senior Lecturer, Reader and Professor, and Consultant at Moorfields Eye Hospital. He changed his main interests from neuro-ophthalmology to retina, following which a specialized clinical service was established at the hospital. Over the years, a productive multidisciplinary research team and investigative capabilities developed for investigation of monogenic retinal disorders and age-related macular disease. Investigative techniques included molecular genetics, electrophysiology, psychophysics, specialised imaging and morphology. In order to contribute fully to research, he spent a sabbatical period with Dr Dean Bok at UCLA in 1985.
José-Alain Sahel is Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris, France, and Cumberlege Professor of Biomedical Sciences at the Institute of Ophthalmology-University College London, UK. He is Chairman of Departments of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation. José Sahel is founder and director of the Vision Institute in Paris, a site for translational research on treatments for currently untreatable inherited and age-related ocular diseases.
José Sahel sits on several scientific and editorial boards, including the Executive SAB of Foundation Fighting Blindness. He has been the recipient of numerous awards, including Foundation Fighting Blindness Trustee Award, Alcon Research Institute Award for Excellence in Vision Research, Grand Prix NRJ-Neurosciences-Institut de France, CNRS Medal of Innovation, Jules Gonin lecture and the Prize of the of the Retina Research Foundation.
José Sahel was elected to the European Academy of Ophthalmology (2006), the Academia Ophthalmologia Internationalis (2007), the Academy of Sciences-Institut de France (2007) and the German National Academy of Sciences Leopoldina (2014). He is Honorary Member of the Deutsche Ophthalmologische Gesellschaft, Knight of Ordre National de la Légion d’Honneur and Honoris Causa Doctorate of the University of Geneva. He was a Founder and Chief Scientific Advisor of Fovea, which became the ophthalmological division of Sanofi-Aventis, and is currently a scientific co-founder of GenSight Biologics and Pixium Vision.
Dr. Susan Orr has held a range of leadership roles within the ophthalmic industry over the past 17 years, spanning US & International Clinical Development, Academic Collaborations, Business Development, and New Product Strategy during 16 years at Alcon. Most recently, after joining Janssen, the pharmaceutical division of Johnson & Johnson, she is charged with developing Ophthalmic Medical Affairs capabilities to support Janssen’s retina program. Prior to industry, Dr. Orr practiced optometry in Ottawa, Canada for 10 years and is an alumnus of the University of Waterloo, School of Optometry.
For the past ten years, Dr. Orr has focused on the retina landscape and innovation within the space, identifying and leading the evaluation of external pharmaceutical and device assets that contributed to the growth of the R&D pipeline. Her interests focus on novel, differentiated approaches to solving unmet needs, consistent with Janssen’s cell therapy program for AMD. While at Alcon, she participated in the development of more than 10 products that achieved approval in multiple regions. Dr. Orr entered private practice in Ottawa, where she became active in political action related to health care initiatives. She is currently on the advisory board of OWL (Ophthalmic Women Leaders) as well as Chair of the Ophthalmic Industry Professionals (OIP) within OWL. Dr. Orr is currently pursuing an MBA in Strategic Planning.
Adrienne L. Graves, Ph.D. is a visual scientist by training and a global industry leader in ophthalmology. Dr. Graves is the former President and CEO of Santen Inc, and was named the first woman and first non-Japanese global corporate officer of Santen Ltd. Prior to her 15 years at Santen, Dr. Graves spent nine years with Alcon, beginning as a Senior Scientist and progressing through various roles, including Director of International Ophthalmology.
Dr. Graves currently serves as an Independent Director on the following corporate boards: Akorn, Inc., TearLab, Nicox, Envisia Therapeutics, Aerpio Therapeutics, and Encore Vision. She is also a Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation.
Dr. Graves co-founded Glaucoma 360 and Ophthalmic Women Leaders (OWL). She received her undergraduate degree from Brown University, her PhD from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris (France).
He received his undergraduate degree and doctorate from Union University, Albany, NY and earned his post-doctorate degree from Rutgers University, NJ. Prior to joining Santen, he was Global Head of Marketing and Sales at Thrombogenics, Inc. where he led the commercial launch for Jetrea®.
Previously, Dr. Palanki served as Director of Global Marketing and Sales at NeoVista, Inc., and earlier in his career, held several positions at Genentech as part of the team that developed and launched Lucentis®. Prior to Genentech, he worked at Eyetech Pharmaceuticals as part of the initial team submitting the NDA for Macugen™ , and at Novartis Pharmaceuticals oncology business unit in the New Product Commercialization group. Dr. Palanki also serves as an advisory board member to mobile healthcare and ophthalmology start-ups in the bay area and other parts of the US.
Pravin U. Dugel, MD graduated Summa Cum Laude from Columbia University in the City of New York. He then attended UCLA School of Medicine, followed by residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.
Dr. Dugel joined Retinal Consultants of Arizona in July 1994 and is currently Managing Partner, Retinal Consultants of Arizona; Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; Founding Member, Spectra Eye Institute, Sun City; Physician Executive Director, Banner Eye Institute, Banner University Medical Center, University of Arizona.
Dr. Dugel has authored innumerable papers and book chapters and has been invited to lecture at prestigious meetings, Visiting Professorships and Universities worldwide. He is on the Editorial Board of several major-medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a primary investigator in over 100 multicenter clinical trials. He has been elected Subspecialty Day Board Chairman for the American Academy of Ophthalmology, to the Board of Directors of the American Society of Retina Specialists, and to the largest retina society in Europe, EuRetina. He serves on the Scientific Advisory Board of numerous companies, including Aerpio, Alcon, Digisight, Genentech, Novartis, Ophthotech, Opthea, Roche, and TrueVision.
In Arizona, he has served as President of the Phoenix Ophthalmology Society and is on the Board of Directors of the Arizona Ophthalmology Society. Since 1994, Dr. Dugel has been a member of the U.S. Department of Health and Human Services agency, providing eye care services to Native Americans. He has co-founded a scholarship and mentorship program – Project SENA – with his two daughters, creating educational opportunities for Native American youth and adults.
Dr. Dugel is Chairman of the ORBIS (“Flying Eye Hospital”) International Medical Advisory Board and the Medical Strategic Committee. With ORBIS, he travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.
In 2017, Dr. Dugel was inducted into the “Retina Hall of Fame,” which honors ophthalmologists for their exceptional lifetime achievements and contributions to the field of retina.
Prof. Wong is a senior consultant ophthalmologist sub-specializing in medical retina at the Singapore National Eye Centre (SNEC). He is also the Provost’s Chair of Ophthalmology at Duke-NUS Medical School, National University of Singapore where he is concurrently Vice-Dean, Office of Clinical Sciences.
Prof. Wong is a physician-scientist, practicing as a retinal specialist and with a broad-based research focused on the epidemiology and clinical treatment outcomes of retinal diseases, such as diabetic and hypertensive retinopathy and age-related macular degeneration. He has published more than 1,000 peer-reviewed papers, including papers in the New England Journal of Medicine and the Lancet, has given more than 300 invited named, plenary and symposium lectures. He chairs the International Council of Ophthalmology’s Committee on Diabetic Eye Care, sits on many international professional bodies, and is on Editorial Boards of JAMA Ophthalmology, IOVS, Diabetes Care, and other journals.
Dr Rajat N Agrawal is an ophthalmologist and a retina specialist, known for his clinical acumen, research work (he is a co-inventor & a co-patent holder of ARGUS-II) and interest in teaching, as well as his social commitment.
Dr Agrawal completed his medical education and residency in Nagpur & Mumbai (formerly Bombay), before heading to join Sankara Nethralaya, Chennai, India, for a retina fellowship. He joined the Institute as a faculty after the completion of the fellowship and worked for seven years, before heading to Hong Kong on an invitation to teach, train and manage/operate complicated cases at the Chinese University of Hong Kong. Later, he was invited to the Commonwealth of the Bahamas, where he was the only Retina Specialist in the country & Director of the Ophthalmology Program at the Princess Margaret Hospital in Nassau, as well as the Residency Director for residents from Yale University Department of Ophthalmology. In 2003, he joined USC/Doheny Eye Institute in Los Angeles, CA, where he was involved, apart from clinical care and teaching, in ideation, research & development of the ARGUS-II, devising the surgical procedure for the implant procedure and the clinical trials that followed in six centers in the US and four in Europe. ARGUS-II is currently the only approved treatment for advanced retinitis pigmentosa in the US and in Europe at this time. Dr Agrawal also has a Masters degree in Regulatory Sciences from USC.
Dr Agrawal is the President & CEO of Retina Global.